Pearly Shuyi Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pearly Shuyi Ng has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Roderick Wayland Bates
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore 637371, Singapore
4 shared publications Boping Liu
3 shared publicationsChoon Heng Low
3 shared publications- Gerhard Grüber
School of Biological Sciences Nanyang Technological University Singapore Republic of Singapore
3 shared publications - Kevin Pethe
Singapore Centre for Environmental Life Sciences Engineering, School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
3 shared publications Qian Wen Tan
3 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2130-2144
A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis
The Mycobacterium tuberculosis cytochrome bcc:aa3 (cyt-bcc:aa3) oxidase is a validated drug target for tuberculosis treatment. In addition to telacebec (Q203), a clinical-stage drug candidate, several preclinical cyt-bcc:aa3 inhibitors have been reported. However, the bactericidal potency of cyt-bcc:aa3 inhibitors is limited by cytochrome bd oxidase (cyt-bd), an alternative terminal oxidase. We developed a high-throughput whole-mycobacteria assay to identify new cyt-bd inhibitors. Screening 115,398 small molecules identified several new chemical series, including a pyrazolo-quinazoline amine series. Chemical optimization yielded the potent derivative ETX1975-3, which, in combination with Q203, is bactericidal against M. tuberculosis, retains activity against a panel of M/XDR M. tuberculosis clinical isolates, and also shows efficacy against nontuberculous mycobacteria (NTM). Mode of action studies validated the cyt-bd target as the molecular target. While further chemical optimization is required, favorable microbiological, ADMET, and in vivo potency of ETX1975-3 makes it a promising preclinical candidate for tuberculosis and NTM infections.
- 13 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2130-2144
Open AccessA Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis
The Mycobacterium tuberculosis cytochrome bcc:aa3 (cyt-bcc:aa3) oxidase is a validated drug target for tuberculosis treatment. In addition to telacebec (Q203), a clinical-stage drug candidate, several preclinical cyt-bcc:aa3 inhibitors have been reported. However, the bactericidal potency of cyt-bcc:aa3 inhibitors is limited by cytochrome bd oxidase (cyt-bd), an alternative terminal oxidase. We developed a high-throughput whole-mycobacteria assay to identify new cyt-bd inhibitors. Screening 115,398 small molecules identified several new chemical series, including a pyrazolo-quinazoline amine series. Chemical optimization yielded the potent derivative ETX1975-3, which, in combination with Q203, is bactericidal against M. tuberculosis, retains activity against a panel of M/XDR M. tuberculosis clinical isolates, and also shows efficacy against nontuberculous mycobacteria (NTM). Mode of action studies validated the cyt-bd target as the molecular target. While further chemical optimization is required, favorable microbiological, ADMET, and in vivo potency of ETX1975-3 makes it a promising preclinical candidate for tuberculosis and NTM infections.
- Open Access
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1135-1153
Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model
Chagas Disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi, affecting millions worldwide. Current treatments suffer from variable efficacy, long duration, and safety concerns, highlighting the need for better therapies. A phenotypic screening of the Novartis compound library against Trypanosoma brucei identified cyanotriazole (CT) compounds with rapid sterilizing activity across kinetoplastids via selective inhibition of parasite topoisomerase II. First-generation CTs had safety liabilities, including lymphopenia and neutrophilia due to sphingolipid pathway modulation. Medicinal chemistry optimization led to a tailored aminopyrrolidine core structure for Chagas Disease, improving ADME properties and reducing off-target effects. IID432 showed potent activity against T. cruzi (EC50 = 8 nM) and achieved a relapse-free cure in a chronic mouse model of infection with shorter treatment duration. These findings support IID432 as a promising fast-acting, curative therapy for T. cruzi infections.
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1135-1153
Open AccessDiscovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model
Chagas Disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi, affecting millions worldwide. Current treatments suffer from variable efficacy, long duration, and safety concerns, highlighting the need for better therapies. A phenotypic screening of the Novartis compound library against Trypanosoma brucei identified cyanotriazole (CT) compounds with rapid sterilizing activity across kinetoplastids via selective inhibition of parasite topoisomerase II. First-generation CTs had safety liabilities, including lymphopenia and neutrophilia due to sphingolipid pathway modulation. Medicinal chemistry optimization led to a tailored aminopyrrolidine core structure for Chagas Disease, improving ADME properties and reducing off-target effects. IID432 showed potent activity against T. cruzi (EC50 = 8 nM) and achieved a relapse-free cure in a chronic mouse model of infection with shorter treatment duration. These findings support IID432 as a promising fast-acting, curative therapy for T. cruzi infections.
- 7 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17087-17102
Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity
Resulting in several million deaths globally, the COVID-19 pandemic has highlighted the criticality of antiviral drugs during a viral pandemic. Herein, we describe our efforts toward targeting SARS-CoV-2 Mpro, a key viral protease, which led to the discovery of compound 18, a reversible covalent inhibitor with potent antiviral activity against several clinical variants of SARS-CoV-2. Compound 18 demonstrated dose-dependent efficacy in a mouse-adapted SARS-CoV-2 infection model, with favorable pharmacokinetic profiles in mice, rats, dogs, and monkeys.
- 7 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17087-17102
Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity
Resulting in several million deaths globally, the COVID-19 pandemic has highlighted the criticality of antiviral drugs during a viral pandemic. Herein, we describe our efforts toward targeting SARS-CoV-2 Mpro, a key viral protease, which led to the discovery of compound 18, a reversible covalent inhibitor with potent antiviral activity against several clinical variants of SARS-CoV-2. Compound 18 demonstrated dose-dependent efficacy in a mouse-adapted SARS-CoV-2 infection model, with favorable pharmacokinetic profiles in mice, rats, dogs, and monkeys.
- 30 October 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (45) , 31321-31329
Button-Push On-Demand Synthesis for Rapid Optimization of Antiviral Peptidomimetics
The optimization of hit compounds into drug candidates is a pivotal phase in drug discovery but often hampered by cumbersome manual synthesis of derivatives. While automated organic molecule synthesis has enhanced efficiency, safety, and cost-effectiveness, achieving fully automated multistep synthesis remains a formidable challenge due to issues such as solvent and reagent incompatibilities and the accumulation of side-products. We herein demonstrate an automated solid-phase flow platform for synthesizing α-keto-amides and nitrile peptidomimetics, guided by docking simulations, to identify potent broad-spectrum antiviral leads. A compact parallel synthesizer was built in-house, capable of producing 5 distinct molecules per cycle; 525 reactions could be finished within three months to generate 42 derivatives for a structure-activity relationship (SAR) investigation. Among these, ten derivatives exhibited promising target inhibitory activity (IC50 < 100 nM) including two with antiviral activity (EC50 < 250 nM). The platform, coupled with digital chemical recipe files, offers rapid access to a wide range of peptidomimetics, serving as a valuable reservoir for broad-spectrum antiviral candidates. This automated solid-phase flow synthesis approach expedites the generation of previously difficult complex molecular scaffolds. By integration of SPS-flow synthesis with medicinal chemistry campaign, >10-fold target inhibitory activity was achieved from a small set of derivatives, which indicates the potential to shift the paradigm of drug discovery.
- 30 October 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (45) , 31321-31329
Button-Push On-Demand Synthesis for Rapid Optimization of Antiviral Peptidomimetics
The optimization of hit compounds into drug candidates is a pivotal phase in drug discovery but often hampered by cumbersome manual synthesis of derivatives. While automated organic molecule synthesis has enhanced efficiency, safety, and cost-effectiveness, achieving fully automated multistep synthesis remains a formidable challenge due to issues such as solvent and reagent incompatibilities and the accumulation of side-products. We herein demonstrate an automated solid-phase flow platform for synthesizing α-keto-amides and nitrile peptidomimetics, guided by docking simulations, to identify potent broad-spectrum antiviral leads. A compact parallel synthesizer was built in-house, capable of producing 5 distinct molecules per cycle; 525 reactions could be finished within three months to generate 42 derivatives for a structure-activity relationship (SAR) investigation. Among these, ten derivatives exhibited promising target inhibitory activity (IC50 < 100 nM) including two with antiviral activity (EC50 < 250 nM). The platform, coupled with digital chemical recipe files, offers rapid access to a wide range of peptidomimetics, serving as a valuable reservoir for broad-spectrum antiviral candidates. This automated solid-phase flow synthesis approach expedites the generation of previously difficult complex molecular scaffolds. By integration of SPS-flow synthesis with medicinal chemistry campaign, >10-fold target inhibitory activity was achieved from a small set of derivatives, which indicates the potential to shift the paradigm of drug discovery.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 26 April 2020
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (32) , 13295-13304
Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
The F1FO‐ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium‐specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti‐tuberculosis F‐ATP synthase inhibitors.
- 26 April 2020
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (32) , 13295-13304
Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
The F1FO‐ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium‐specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti‐tuberculosis F‐ATP synthase inhibitors.
- 26 April 2020
- Published by Wiley in Angewandte Chemie
- Vol. 132 (32) , 13397-13406
Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
The F1FO‐ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium‐specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti‐tuberculosis F‐ATP synthase inhibitors.
- 26 April 2020
- Published by Wiley in Angewandte Chemie
- Vol. 132 (32) , 13397-13406
Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
The F1FO‐ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium‐specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti‐tuberculosis F‐ATP synthase inhibitors.
- 1 October 2016
- Published by Elsevier in Tetrahedron
- Vol. 72 (41) , 6356-6362
Synthesis of hydroxylated pyrrolidines by allenic cyclisation
- 1 October 2016
- Published by Elsevier in Tetrahedron
- Vol. 72 (41) , 6356-6362
Synthesis of hydroxylated pyrrolidines by allenic cyclisation
- 1 December 2015
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 106, 144-156
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
- 1 December 2015
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 106, 144-156
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents